Trial Profile

COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solnatide (Primary)
Indications Adult respiratory distress syndrome; Pulmonary oedema
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Sep 2021 Status changed from recruiting to discontinued.
04 May 2020 According to an APEPTICO Forschung und Entwicklung GmbH media release, The clinical study at the Medical University Vienna has been submitted for co-funding within the framework of the Corona Emergency Call to the Austrian Research Promotion Agency (FFG).
23 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com